Clinical Features of Different Genotypes/genogroups of Human Metapneumovirus in Hospitalized Children
Overview
Microbiology
Affiliations
Background/purpose(s): To explore the clinical features of different human metapneumovirus (hMPV) genotypes/genogroups in hospitalized children.
Methods: From January 2005 to April 2010, 3313 children's respiratory specimens sent for the detection of respiratory syncytial virus antigen were also tested for hMPV by real time-polymerase chain reaction. Demographics, clinical presentations, and laboratory findings of patients infected with different genotypes/genogroups of hMPV were compared.
Results: A total of 725 samples were positive for hMPV (positive rate, 23%). The F gene was sequenced for 279 isolates; of these, genotype A was identified in 51% (A1, 6.1%; A2, 45%) and genotype B in 49% (B1, 19%; B2, 30%). Medical records of 152 hospitalized children were reviewed. Co-infection with other pathogens was 25.7% (39/152). Excluding co-pathogens other than respiratory syncytial virus, a total of 124 children were analyzed. The most common symptoms included cough, fever, rhinorrhea, wheezing and respiratory distress with accessory muscle usage. The main diagnosis was bronchiolitis. The most common chest radiographic findings were increased perihilar infiltrates. No significant difference was found in terms of demographics, clinical manifestations, and laboratory findings among the children infected with different serogroups of hMPV.
Conclusion: hMPV accounted for a substantial proportion of hospitalized children with lower respiratory tract infection with a high co-infection rate. The A2 subgroup was the most frequently observed, followed by B2. No significant difference was found among patients infected with different genotypes/genogroups of hMPV in terms of clinical manifestations.
Epidemiology of human metapneumovirus in Taiwan from 2013 to 2023.
Yang S, Chiu T, Tsai K, Li C, Yang J, Liu M Arch Virol. 2024; 169(11):229.
PMID: 39441325 PMC: 11499400. DOI: 10.1007/s00705-024-06147-8.
Distinct roles for type I and type III interferons in virulent human metapneumovirus pathogenesis.
Zhang Y, Xu J, Miranda-Katz M, Sojati J, Tollefson S, Manni M PLoS Pathog. 2024; 20(2):e1011840.
PMID: 38315735 PMC: 10868789. DOI: 10.1371/journal.ppat.1011840.
Otomaru H, Nguyen H, Vo H, Toizumi M, Le M, Mizuta K Sci Rep. 2023; 13(1):15757.
PMID: 37735242 PMC: 10514255. DOI: 10.1038/s41598-023-42692-z.
Engineering of Live Chimeric Vaccines against Human Metapneumovirus.
Ogonczyk Makowska D, Hamelin M, Boivin G Pathogens. 2020; 9(2).
PMID: 32093057 PMC: 7168645. DOI: 10.3390/pathogens9020135.
Lim Y, Kweon O, Kim H, Kim T, Lee M Clin Infect Dis. 2019; 70(12):2683-2694.
PMID: 31353397 PMC: 7108157. DOI: 10.1093/cid/ciz697.